Loading
Life sciences · Journal article
Cancers · September 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background/Objectives: Our previous study identified ZBTB1 as a novel tumor suppressor in estrogen receptor-positive (ER+) breast cancer. Moreover, The Cancer Genome Atlas (TCGA) data analysis showed a much lower level of ZBTB1 in triple-negative breast cancer than in ER+ breast cancer. Triple negative breast cancer (TNBC) lacks effective targeted therapies and largely depends on chemotherapy, while chemotherapy resistance remains a major clinical challenge. This study aimed to explore the role of ZBTB1 in TNBC progression and chemotherapy resistance. Methods: We performed clinical survival analysis, in vitro and in vivo functional experiments, mass spectrometry screening, and mechanistic validation in TNBC and Adriamycin-resistant TNBC cells. Results: We found that ZBTB1 protein is downregulated in TNBC and this downregulation correlates with shorter patient survival. ZBTB1 regulates glycolysis and chemotherapy resistance in TNBC cells. Mechanistically, ZBTB1 interacts with c-Myc and suppresses its transcriptional activity in MDA-MB-231 and MDA-MB-453 but not in Adriamycin-resistant cells (MDA-MB-231/ADR and MDA-MB-453/ADR). LncRNA SAP30L-AS1 is required for maintaining the ZBTB1–c-Myc interaction in TNBC cells. SAP30L-AS1 is significantly depleted in Adriamycin-resistant cells, which disrupts the binding between ZBTB1 and c-Myc. Functional validation revealed that SAP30L-AS1 modulates glycolysis and chemotherapy resistance in TNBC cells in a ZBTB1-dependent manner. Conclusions: Collectively, our data indicate the key role of ZBTB1 in TNBC and ZBTB1 may serve as a novel approach for TNBC treatments.